MFLRC Academy is live. On-demand regulatory training. Lesson 1 is free. Explore→

MFLRC Academy — on-demand training in Health Canada licensing, GMP and quality systems. Browse courses →

MFLRC - MF License & Regulatory Consultants

November 22, 2026 · Pharmaceuticals

When FDA Says Hire a CGMP Consultant: 21 CFR 211.34 Explained

By Mussarat Fatima

PharmaceuticalsGMPCompliance
When FDA Says Hire a CGMP Consultant: 21 CFR 211.34 Explained

Read almost any FDA warning letter to a drug manufacturer in 2026 and you will find the same line near the end: engage a qualified consultant under 21 CFR 211.34. The November 2026 letters to LGM Pharma Solutions, USV Private Limited and Umicore Argentina all carried a version of it, each paired with a call for a comprehensive six-system audit. For a firm that has just received a warning letter, that recommendation raises urgent questions. What does the rule actually require? What should the consultant do? And how do you pick one who will fix the problem rather than paper over it?

This article explains what 21 CFR 211.34 says, why FDA keeps pointing firms to it, what a six-system audit covers, and how to select and oversee a consultant so the engagement holds up with FDA. It is written for executives and quality leaders who need to respond quickly and defensibly, not add another line item that changes nothing.

Executive summary

  • 21 CFR 211.34 is short: consultants must have sufficient education, training and experience for the work, and the firm must keep records of each consultant's name, address, qualifications and the service they provide.
  • FDA recommends a consultant when the violations suggest the firm cannot fix the problem on its own. It is a signal about the depth of the issue, not a box to tick.
  • The paired six-system audit covers Quality, Facilities and Equipment, Materials, Production, Packaging and Labeling, and Laboratory Control.
  • A consultant does not transfer liability. FDA states plainly that using a consultant does not relieve the firm's obligation to comply, and executive management stays responsible.
  • Selection matters. Independence, relevant dosage-form experience, and willingness to deliver uncomfortable findings separate a useful consultant from an expensive one.

What does 21 CFR 211.34 actually say?

21 CFR 211.34 is one of the shortest regulations in the finished-pharmaceutical CGMP rules. In full, it requires that consultants advising on the manufacture, processing, packing or holding of drug products have sufficient education, training and experience, or a combination of these, to advise on the subject for which they are retained. It also requires that records be kept stating the name, address and qualifications of any consultants and the type of service they provide.

Two obligations follow from that short text. First, the consultant must be genuinely qualified for the specific work. A generalist is not automatically qualified to advise on sterile manufacturing or a specific analytical method. Second, you must be able to prove it. The qualification records are part of your quality system, and an inspector can ask to see them. If you cannot show why the consultant was suitable, the engagement itself becomes a gap.

Why FDA recommends a consultant

FDA does not recommend a consultant for every finding. It does so when the nature of the violations suggests systemic weakness, the kind a firm may not be able to see or fix with its own resources. The LGM Pharma letter puts it directly: based on the nature of the violations identified, the firm should engage a consultant qualified under 21 CFR 211.34 to assist in meeting CGMP requirements, and that consultant should perform a comprehensive six-system audit and evaluate the completion and effectiveness of all corrective and preventive action before the firm pursues resolution of its compliance status with FDA.

The pattern repeats across recent letters. USV Private Limited, an aseptic manufacturer, was told to engage a consultant under 211.34 and complete a six-system audit after FDA found airflow and aseptic deficiencies. Umicore Argentina, an active pharmaceutical ingredient maker, was told to bring in a qualified independent consultant and conduct a six-system audit after more than 300 out-of-specification results and water system failures. When the recommendation appears, FDA is telling you that it doubts the firm can diagnose itself. For how the consultant fits a wider remediation, see our FDA warning letter production restart playbook.

The six-system audit: what the consultant must cover

FDA inspects drug manufacturers using a systems-based model with six systems. A comprehensive six-system audit means the consultant evaluates each one, not just the area named in the warning letter. The table below outlines what each system covers.

SystemWhat the consultant audits
Quality systemGovernance, quality unit authority, CAPA, change control, deviations, complaints, management review and the state of the overall QMS.
Facilities and equipmentFacility design, maintenance, cleaning, qualification, calibration, and utilities such as water and HVAC.
MaterialsSupplier qualification, receipt and testing of components, storage, and control of in-process and finished materials.
ProductionProcess validation, batch records, in-process controls, and the state of control of manufacturing.
Packaging and labelingLine clearance, label control, reconciliation, and prevention of mix-ups.
Laboratory controlMethod validation, OOS handling, stability, data integrity, and release testing.

The audit's value is in the connections it finds. A laboratory OOS problem is often rooted in a weak quality system, and an aseptic finding often traces back to facilities or production. A consultant who audits only the cited area will miss the systemic link that FDA expects you to close. Our work on why CAPA keeps failing shows how often the true root cause sits in a different system than the symptom.

What a consultant does not do

A consultant does not take on your liability. FDA is explicit: using a consultant does not relieve the firm's obligation to comply with CGMP, and the firm's executive management remains responsible for resolving all deficiencies and systemic flaws. The consultant advises, audits and verifies. Management owns the decisions, the resources and the outcome. A firm that treats a consultant as a shield, rather than a tool, tends to produce a thick report and little real change, which is exactly what a follow-up inspection will expose.

How to select a CGMP consultant: six steps

  1. Match the expertise to the finding. A sterile airflow problem needs aseptic and Annex 1 experience; a validation finding needs process validation depth. Ask for specific, relevant engagements, not a general CGMP resume.
  2. Insist on independence. The consultant should be free to deliver findings you will not like. A consultant who depends on your approval for repeat work has an incentive to go easy, which defeats the purpose.
  3. Check the qualification records you will keep. Before engaging, confirm you can document the consultant's education, training and experience for this specific work. That record is a 211.34 requirement.
  4. Scope the six-system audit in writing. Define which systems, sites and products are covered, and require evaluation of CAPA completion and effectiveness, not just a list of observations.
  5. Agree how findings reach FDA. Decide in advance how the audit report, CAPA verification and management responses will be summarised in your correspondence with the agency, so the engagement supports, not complicates, your response.
  6. Keep management in the loop. Build in executive review of findings and decisions. FDA holds management responsible, so management must be visibly engaged throughout.

The Canadian angle: Health Canada and consultants

Canadian Good Manufacturing Practices, set out in the Food and Drug Regulations, Part C, Division 2 and explained in Health Canada's GUI-0001, do not contain a clause worded exactly like 211.34. The expectation is the same in substance: personnel and advisers must be qualified for their roles, and a firm remediating serious findings is expected to use competent support and to document it. If you export to the United States, the 211.34 recommendation can appear in a U.S. letter even when your Health Canada file is in order, so Canadian manufacturers with FDA exposure should understand both systems. Our Health Canada GMP inspection readiness self-assessment and our guide to responding to an FDA Form 483 or a Health Canada inspection help you prepare for both.

CGMP consultant engagement checklist

  • The consultant's education, training and experience match the specific findings, and this is documented.
  • A record of the consultant's name, address, qualifications and service is kept in the quality system.
  • The six-system audit scope is defined in writing and covers all six systems.
  • The engagement evaluates CAPA completion and effectiveness, not just open observations.
  • The consultant is independent enough to deliver unwelcome findings.
  • Executive management reviews findings and owns the remediation decisions and resources.
  • There is a clear plan for how the work is summarised in correspondence with FDA before resolution is pursued.

Common mistakes

The most common mistake is hiring for reassurance instead of rigour. A consultant who confirms that everything is nearly fine is worthless after a warning letter, because FDA already disagrees. The second is scoping the audit too narrowly, limiting it to the cited area so the systemic root cause is never found. The third is treating the engagement as a liability transfer; management disengages, and the follow-up inspection finds the same culture that produced the original findings. The fourth is failing to keep the 211.34 qualification record, so the firm cannot even show that its chosen consultant was suitable.

A related trap is confusing a quality agreement with a consulting engagement. If your remediation touches a contract manufacturer, the governance still has to be right on paper; see our guide to CDMO quality agreement clauses inspectors expect.

Frequently asked questions

What does FDA mean by a qualified consultant under 21 CFR 211.34?

FDA means a consultant with sufficient education, training and experience to advise on the specific subject for which they are retained, with records kept of their name, address, qualifications and the service provided. The qualification must fit the actual findings, not just general CGMP familiarity.

Is hiring a consultant mandatory after a warning letter?

FDA recommends it rather than ordering it, but the recommendation signals that the agency doubts the firm can remediate alone. Ignoring it, and then failing to fix the problem, makes the firm's position worse. Most firms in this situation do engage qualified support.

What is a six-system audit?

It is an evaluation of the six systems FDA uses to inspect drug manufacturers: Quality, Facilities and Equipment, Materials, Production, Packaging and Labeling, and Laboratory Control. After a warning letter, FDA often asks that a qualified consultant audit all six and verify CAPA effectiveness.

Does a consultant make the firm compliant?

No. FDA states that using a consultant does not relieve the firm's obligation to comply, and executive management remains responsible for resolving deficiencies. The consultant advises and verifies; the firm must act.

Does Health Canada require a consultant under a 211.34 equivalent?

There is no identical clause in Canadian GMP, but Health Canada expects qualified personnel and advisers and accepts documented third-party support during remediation. Canadian firms that export to the United States should still understand the 211.34 expectation.

How do I choose between consultants?

Match the expertise to the finding, require independence, confirm you can document their qualifications, scope the six-system audit in writing, and keep management engaged. A consultant willing to tell you hard truths is worth more than one who reassures you.

How MFLRC can help

MF License & Regulatory Consultants (MFLRC) provides the kind of qualified, independent support FDA points to under 21 CFR 211.34. We conduct six-system audits and mock FDA inspections, carry out gap assessments against CGMP and Health Canada GMP, and verify CAPA completion and effectiveness so your remediation stands up to a follow-up inspection. Our team brings senior-level quality assurance and regulatory experience across pharmaceuticals, natural health products, cannabis, medical devices and food, with deep Canadian expertise and cross-border FDA and EU knowledge.

We also support SOP development, quality system remediation, supplier qualification and validation, and we document engagements so your 211.34 qualification record is in place from the start. If you have received a warning letter or a Form 483, or you want to test your systems before an inspector does, we can scope the right engagement with you.

Conclusion

When FDA recommends a consultant under 21 CFR 211.34, it is making a judgement about the depth of your problem. The rule itself is short, but the expectation behind it is serious: bring in genuinely qualified help, audit all six systems, verify that your corrective actions actually worked, and keep management accountable throughout. Choose for rigour, not reassurance, document the qualification, and treat the consultant as a tool rather than a shield. Done well, the engagement does more than satisfy FDA; it rebuilds the quality system that produced the findings in the first place.

Sources and references

Downloadable Resource

Choosing a CGMP Consultant: A Buyer's Checklist

A one-page checklist for selecting, scoping and overseeing a qualified CGMP consultant under 21 CFR 211.34, including the six-system audit.

File: MFLRC-CGMP-Consultant-Checklist.pdf

Share with others

Tags

CGMPWarning LettersRemediationInspection ReadinessCAPAQuality Management SystemFDAPharmaceuticals